Innate Pharma Showcases Abstracts for EHA 2024 Congress

Innate Pharma SA, a biotechnology company listed on Euronext Paris and Nasdaq, has announced that four abstracts featuring its drug candidates have been accepted for presentation at the European Association of Hematology (EHA) 2024 Congress. The event is scheduled to take place from June 13-16, 2024, in Madrid, Spain. The abstracts focus on two of Innate Pharma's advanced drug candidates: SAR443579 (IPH6101) and IPH6501, both of which are part of the company’s innovative ANKET® platform.

The first pair of abstracts centers on SAR443579 (IPH6101), a trifunctional anti-CD123 NKp46xCD16 NK cell engager being developed in collaboration with Sanofi for the treatment of blood cancers. SAR443579 is currently undergoing a Sanofi-sponsored Phase 1/2 clinical trial as a monotherapy. The first abstract, titled "Completed dose-escalation from the First-in-Human, Phase 1/2 Study of CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk-Myelodysplasia," will be presented orally. The second, a poster presentation titled "Exploring Dose-response Relationship of a Novel CD123 NK Cell Engager SAR443579 in Acute Myeloid Leukemia (AML) Models," will delve into the dose-response relationship of this novel drug in AML models.

The second pair of abstracts pertains to IPH6501, Innate Pharma’s second-generation ANKET® drug candidate for treating relapsed or refractory CD20-expressing B-cell Non-Hodgkin's Lymphoma. This drug is also in a Phase 1/2 clinical trial. The first abstract, "Preclinical assessment of IPH6501, a first-in-class IL2V-armed tetraspecific NK Cell Engager directed against CD20 for R/R B-NHL, in comparison with a CD20-targeting T Cell Engager," will be presented as a poster and is embargoed until May 23, 2024. The second abstract, “A Phase 1/2 trial investigating safety, tolerability, and preliminary antitumor activity of IPH6501, a first-in-class NK Cell Engager, in patients with R/R CD20-expressing NHL,” will be included in the EHA abstracts book.

Dr. Sonia Quaratino, Chief Medical Officer of Innate Pharma, expressed her enthusiasm about the presentations, highlighting the potential therapeutic benefits of NK Cell Engagers for patients with significant unmet medical needs.

The ANKET® (Antibody-based NK cell Engager Therapeutics) platform represents Innate Pharma's proprietary technology aimed at developing next-generation, multi-specific natural killer (NK) cell engagers to combat cancer. This platform is designed to create new classes of molecules that stimulate synthetic immunity against cancer.

IPH6501, specifically, is an NK cell engager that co-activates receptors on NK cells using a variant of human IL-2, bypassing the alpha subunit, and targeting the CD20 tumor antigen. This results in targeted proliferation and activation of NK cells, enhancing their ability to destroy CD20-expressing malignant cells. Preclinical models have demonstrated that IPH6501 offers superior anti-tumor efficacy compared to existing benchmark antibodies.

Innate Pharma’s collaborative relationship with Sanofi dates back to a 2016 research and license agreement, which focuses on developing multi-specific antibody formats that engage NK cells to kill tumor cells. Under this agreement, Innate Pharma is eligible for substantial milestone payments and royalties on net sales from Sanofi-developed products.

Innate Pharma, headquartered in Marseille, France, with a U.S. office in Rockville, MD, is dedicated to advancing immunotherapies for cancer patients. Its portfolio includes proprietary programs such as lacutamab, developed for cutaneous T cell lymphomas, and monalizumab, developed with AstraZeneca for non-small cell lung cancer. The company collaborates with major biopharmaceutical firms and research institutions to drive innovation in cancer treatment.